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ABSTRACT
Background: Thyroidectomy is associated with a relatively high incidence of 
postoperative nausea and vomiting (PONV), ranging from 51% to 76%. Because 
these symptoms are distressing for patients, prophylactic medication to avoid or reduce 
PONV is recommended.
Objective: The aim of the present study was to compare the efficacy of ramosetron, 
dexamethasone, and a combination of ramosetron and dexamethasone in preventing 
PONV in Korean women undergoing thyroidectomy.
Methods: In this double-blind, randomized, controlled trial, consecutive adult 
female patients who were scheduled to undergo thyroidectomy under general anesthesia 
at the Kyungpook National University Hospital (Daegu, Korea) were randomly 
assigned to receive ramosetron 0.3 mg alone, dexamethasone 8 mg alone, or a combi-
nation of ramosetron 0.3 mg and dexamethasone 8 mg administered intravenously as 
a single dose immediately after induction of anesthesia. The primary end point of this 
study was the total PONV rate up to 24 hours postanesthesia. The secondary end 
points were the incidence of nausea, incidence of vomiting, severity of nausea (0 = no 
nausea to 10 = nausea as bad as it could be), use of rescue antiemetic drugs, and the 
occurrence of adverse events (AEs) determined through interview or spontaneous 
patient report for 24 hours postanesthesia.
Results: A total of 198 female patients were approached for study inclu-
sion, 18 of whom were excluded. Therefore, 180 Korean women (mean [SD] age, 
46.5 [12.6] years; height, 159.8 [2.7] cm; weight, 53.2 [3.6] kg) were enrolled and 
completed the study. The total PONV rates up to 24 hours postanesthesia were 35%, 
13%, and 10% in the dexamethasone, ramosetron, and combination groups, respec-
tively. The PONV rate was significantly lower in the combination group than in the 
dexamethasone alone group (P = 0.006). The PONV rate was not significantly differ-
ent in the combination group compared with the ramosetron alone group. The PONV 
rate in the dexamethasone alone group was significantly higher than that in the ramosetron 
alone group (P = 0.03). The severity of nausea (median [25th–75th percentiles], 
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0 [0–0] vs 0 [0–4]; P = 0.009) and rate of use of rescue antiemetic drugs (5% vs 27%; 
P = 0.006) were significantly lower in the combination group than in the dexametha-
sone alone group, whereas the severity of nausea (median [25th–75th percentiles], 
0 [0–0] vs 0 [0–0]) and rate of use of rescue antiemetic drugs (5% vs 7%) were not 
significantly different between the combination and ramosetron alone groups. The 
severity of nausea (median [25th–75th percentiles], 0 [0–4] vs 0 [0–0]; P = 0.033) 
and the rate of use of rescue antiemetic drugs (27% vs 7%; P = 0.018) were signifi-
cantly higher in the dexamethasone alone group than in the ramosetron alone group. 
The rates of AEs (headache: 15%, 20%, and 18%; dizziness: 18%, 22%, and 15%) 
were not significantly different in the dexamethasone alone, ramosetron alone, or 
combination groups, respectively.
Conclusions: The combination of ramosetron and dexamethasone was more 
effective in reducing PONV than was dexamethasone monotherapy. However, the 
combination did not show additional benefits compared with ramosetron alone in 
preventing PONV after thyroidectomy in these Korean women. (Curr Ther Res Clin 
Exp. 2010;71:78–88) © 2010 Excerpta Medica Inc.
Key words: thyroidectomy, nausea, vomiting, antiemetics, ramosetron, 
dexamethasone.
INTRODUCTION
Thyroidectomy is associated with a relatively high incidence of postoperative nausea 
and vomiting (PONV), ranging from 51% to 76%.1,2 The etiology of PONV after 
thyroidectomy is not fully understood, but may be associated with several factors, 
including age and sex (mostly middle-aged women), and intense preoperative vagal 
stimulation (surgical handling of neck structures).3 Other factors, including a history 
of motion sickness, smoking, previous postoperative emesis, anesthetic technique, and 
postoperative pain are also considered to be associated with an increase in the inci-
dence of PONV.4 Because these symptoms are distressing for patients, prophylactic 
medication to avoid or reduce PONV is highly recommended.
Several studies have reported that dexamethasone, a corticosteroid, was an ef-
fective antiemetic drug for the prophylaxis of PONV.5–7 In a comprehensive re-
view based on available randomized trials (1996–2001), focused on the effects of 
perioperative single-dose steroid administration, Holte and Kehlet5 reported that 
dexamethasone has antiemetic effects in various types of surgery. In a dose-ranging 
study in 225 women undergoing thyroidectomy, Wang et al6 reported a signifi-
cantly lower incidence of PONV in the dexamethasone group (5 mg) compared 
with the saline group (19% vs 51%; P < 0.01). Fujii and Nakayama7 found that 
the rate of PONV during the first 24 hours after thyroidectomy was signi- 
ficantly lower in the dexamethasone (8 mg) group compared with the placebo 
group (28% vs 76%; P < 0.01). Several currently available 5-hydroxytryptamine-3 
(5-HT3) receptor antagonists (ondansetron, granisetron, dolasetron, and ramose-
tron) are highly effective for PONV, with ramosetron being the newest, most 
potent, and most selective of these agents.8–11 Fujii and Tanaka8,11 reported that 
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85% to 88% of patients undergoing thyroidectomy were emesis-free with ramose-
tron treatment. 
Although 5-HT3 receptor antagonists and dexamethasone are effective for prevent-
ing PONV, none of the currently available pharmacologic interventions totally elimi-
nates PONV. Studies have suggested that the combination of 5-HT3 antagonists 
(eg, dolasetron, granisetron) and dexamethasone, as part of a multimodal approach, 
might reduce PONV more effectively than any drug alone in high-risk patient 
populations.12–14 Fujii et al13 and Biswas and Rudra14 found that adding dexametha-
sone (8 mg) to granisetron (40 mg/kg) administered intravenously before induction of 
anesthesia was associated with improvements in antiemetic efficacy of 12% to 15% 
for 24 hours postanesthesia. A meta-analysis of data from a randomized controlled 
trial (1966–2005) found that combination therapy with a 5-HT3 receptor antagonist 
(granisetron, ondansetron, dolasetron, or tropisetron) and dexamethasone had a safety 
profile similar to that of any agent alone.15
The exact mechanism of action of the combination of dexamethasone with 5-HT3 
receptor antagonists is not yet known. However, dexamethasone may enhance the 
antiemetic efficacy of a 5-HT3 receptor antagonist by inhibiting central or peripheral 
production or secretion of serotonin and by potentiating the main effects of other 
antiemetic drugs by sensitizing the pharmacologic receptors.16
Despite studies reporting on 5-HT3 and steroid combination therapy, no evidence 
is available regarding the effects of a combination of ramosetron and dexamethasone 
for the prevention of PONV. MEDLINE was searched (inception–2009) using the 
following terms: PONV, antiemetics, 5-HT3 receptor antagonist, ramosetron, and dexamethasone. 
The search did not identify any studies regarding the effects of a combination of 
ramosetron and dexamethasone for the prevention of PONV. Therefore, the present 
study was performed to compare the efficacy of a combination of ramosetron and 
dexamethasone with dexamethasone or ramosetron alone in the prevention of PONV 
in adult female patients undergoing thyroidectomy. 
PATIENTS AND METHODS
This double-blind, randomized, controlled study was conducted at the Kyungpook 
National University Hospital (a tertiary care hospital) in Daegu, Korea. Consecutive 
adult female patients were categorized as being a normal healthy patient (American 
Society of Anesthesiologists status I) or a patient with mild systemic disease (status II).17 
All eligible patients were scheduled to undergo thyroidectomy under general anesthe-
sia. The exclusion criteria were as follows: known hypersensitivity or contraindica-
tion to study medication; the use of antiemetics within 24 hours before surgery; the 
presence of gastrointestinal, renal, or liver disease; smoking; a history of motion sick-
ness and/or previous postoperative emesis; pregnancy; or breastfeeding. Because risk 
factors such as sex may contribute to PONV episodes, we controlled the study design 
to include only women. All thyroidectomies were performed by the same team of 
anesthesiologists and surgeons. The study was approved by the institutional review 
board of Kyungpook National University Hospital, and all patients provided written 
informed consent prior to participation. 
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Patients were randomized to treatment group using a computer-generated random 
number table; the group assignment was prepared by the enrolling anesthesiologist in 
sealed opaque envelopes. The enrolling anesthesiologist was not the same person as 
the treating anesthesiologist. A total of 180 sealed envelopes containing the names of 
the groups (60 for each) were prepared before initiation of the study. The envelopes 
were opened before induction of anesthesia, and the drugs were prepared by an inde-
pendent nurse who was not participating in any other part of the study.
No premedication was administered. Anesthesia was induced with propofol 2 mg/kg, 
and rocuronium bromide 1 mg/kg was administered to facilitate tracheal intubation. 
After intubation, anesthesia was maintained with isoflurane titrated between 0.6% to 
2.5% and nitrous oxide 50% in oxygen. Ventilation was mechanically controlled 
and adjusted to maintain the partial pressure of the end-tidal concentration of carbon 
dioxide at 35 to 40 mm Hg. Neuromuscular blockade was reversed with pyridostigmine 
and glycopyrrolate.
Immediately after induction of anesthesia, patients received ramosetron 0.3 mg, 
dexamethasone 8 mg, or a combination of both agents at the aforementioned doses 
administered intravenously as a single dose. Each drug, or placebo (normal saline) 
administered in lieu of active drug, was diluted in 5 mL of clear solution in identical 
syringes. Each patient received 2 syringes, active and placebo in the case of patients in 
the ramosetron alone and the dexamethasone alone groups and both ramosetron and 
dexamethasone in the patients in the combination group. The patients, the anesthesiolo-
gist present during surgery, and the anesthesiologist who collected the postoperative 
data were all blinded with respect to the randomization process and the identity of the 
study drugs.
The primary end point of this study was the total PONV rate up to 24 hours 
postanesthesia. The secondary end points were the incidence of nausea, incidence of 
vomiting, severity of nausea, use of rescue antiemetic drugs, and the occurrence of 
adverse events (AEs) for 24 hours postanesthesia. All episodes of PONV (nausea, retch-
ing, or vomiting) were recorded during the first 24 hours after anesthesia in 2 time 
periods (0–1 hour in the postanesthesia care unit and 1–24 hours in the general ward). 
In the postanesthesia care unit and general ward, an anesthesiologist directly ques-
tioned the patient every 30 minutes and 6 hours, respectively. The anesthesiologist, 
who was blinded to the study groups, asked patients if retching or vomiting had oc-
curred and if they felt nauseated. Vomiting was defined as the forceful expulsion 
of gastric contents from the mouth. For the purpose of data collection, retching (an 
involuntary effort to vomit without the actual expulsion of gastric contents) was con-
sidered vomiting. The presence and severity of nausea were assessed using a 10-point 
scale (0 = no nausea; 10 = nausea as bad as it could be). Metoclopramide 10 mg was 
administered intravenously as a rescue antiemetic drug when patients had a nausea 
score >6 for ≥15 minutes, when they experienced vomiting or retching episodes, or at 
the patient’s request. Postoperative pain was assessed using a 10-point scale (0 = no 
pain to 10 = the worst pain imaginable). Ketorolac (30 mg) as an analgesic was ad-
ministered on request for intolerable pain. The details of any other AEs were noted 
throughout the study and recorded by the treating anesthesiologist during surgery 
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and by the anesthesiologist interviewing patients after the surgery, whether obtained 
through general questioning or reported spontaneously by the patients.
Statistical Analysis
An a priori power analysis based on previous studies in similar surgical populations 
suggested that a group size of 60 would be adequate to determine a 15% difference 
in the incidence of PONV,6,11 the primary end point, given an estimated baseline 
incidence of PONV in the dexamethasone or ramosetron group of 20% (power = 0.80, 
α = 0.05).
Intention-to-treat analysis, which counts all events in all randomized patients, was 
performed. A series of 1-way ANOVAs was conducted to examine differences among the 
3 groups with respect to parametric variables. Primary and other categoric end points 
were compared between groups using the Fisher exact test and continuous end points 
(eg, nausea or pain scores) were compared using the nonparametric Kruskal-Wallis test. 
Where a 3-group treatment test was significant, post hoc pairwise group comparisons 
were made with the Fisher exact test and Mann-Whitney ranked sum test for categoric 
and nonparametric data (eg, severity variables), respectively. All follow-up analyses were 
corrected for the number of simultaneous contrasts using Bonferroni adjustments. P < 
0.05 was considered statistically significant. Number needed to treat (NNT) was calcu-
lated by taking the reciprocal of the absolute risk reduction, and CIs were calculated for 
the NNT.18
RESULTS
A total of 198 female patients were approached for study inclusion, 18 of whom were 
excluded from the study based on the criteria described previously. One hundred 
eighty Korean women (mean [SD] age, 46.5 [12.6] years; height, 159.8 [2.7] cm; 
weight, 53.2 [3.6] kg) completed the study (Table I). No statistically significant 
between-group differences were found in the patients’ demographic and clinical 
characteristics.
The total PONV rates up to 24 hours postanesthesia were 35%, 13%, and 10% in 
the dexamethasone alone, ramosetron alone, and combination groups, respectively. 
The PONV rate was significantly lower in the combination group compared with the 
dexamethasone alone group (95% CI, 0.02–0.18 vs 0.23–0.47; P = 0.006). PONV 
was not significantly different in the combination group than that in the ramosetron 
alone group (95% CI, 0.04–0.22). The incidence of PONV was significantly higher 
in the dexamethasone alone group than that in the ramosetron alone group (P = 0.03) 
(Table II).
Nausea was reported in 12 patients (20%) (95% CI, 0.10–0.30) in the dexametha-
sone alone group, 5 (8%) (95% CI, 0.01–0.15) in the ramosetron alone group, and 4 
(7%) (95% CI, 0.01–0.13) in the combination group (all, P = NS). Vomiting was 
reported in 9 (15%) (95% CI, 0.06–0.24), 3 (5%) (95% CI, 0.00–0.11), and 2 (3%) 
(95% CI, 0.00–0.07) patients in the dexamethasone, ramosetron, and combination 
groups, respectively (all, P < 0.01). Nausea severity was significantly lower in the 
combination group than that in the dexamethasone alone group (median [25th–75th 
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percentiles], 0 [0–0] vs 0 [0–4]; P = 0.009), whereas no significant difference was 
found between the ramosetron alone and combination groups (0 [0–0] vs 0 [0–0]). 
Nausea severity was significantly higher in the dexamethasone alone group than in the 
ramosetron alone group (median [25th–75th percentiles], 0 [0–4] vs 0 [0–0]; P = 
0.033). Rescue antiemetic drugs were required in 16 patients (27%) (95% CI, 0.16–
0.38) in the dexamethasone alone group, 4 (7%) (95% CI, 0.01–0.13) in the ramose-
tron group, and 3 (5%) (95% CI, 0.00–0.11) in the combination group. The inci-
dence of rescue antiemetic drug use was significantly lower in the combination group 
than the dexamethasone group (P = 0.006), whereas no significant difference was 
found between the ramosetron and the combination groups. The incidence of anti- 
emetic rescue drug use was significantly higher in the dexamethasone group than in 
the ramosetron group (P = 0.018). Neither the postoperative pain scores nor the 
percentage of patients requiring ketorolac postoperatively differed significantly be-
tween the 3 groups (Table II).
The NNT to prevent PONV by administering the combination of ramosetron plus 
dexamethasone compared with dexamethasone or ramosetron alone were 4 (95% CI, 
2.55 to 9.30) and 30 (95% CI, –12.29 to 6.75), respectively. The NNT for ramosetron 
compared with dexamethasone was 5 (95% CI, 2.74 to 14.61) (Table III).
The most common AEs observed were headache (9 [15%], 12 [20%], and 
11 [18%] patients) and dizziness (11 [18%], 13 [22%], and 9 [15%] patients) in the 
dexamethasone alone, ramosetron alone, and combination groups, respectively. There 
Table I. Demographic and clinical characteristics of the study patients (N = 180).*
Characteristic
Ramosetron 
0.3 mg 
(n = 60)
Dexamethasone 
8 mg 
(n = 60)
Ramosetron 0.3 mg + 
Dexamethasone 
8 mg 
(n = 60)
Age, mean (SD), y 44.9 (13.3) 45.4 (12.1) 49.1 (12.1)
Height, mean (SD), cm 159.5 (3.1) 160.2 (2.7) 159.8 (2.4)
Weight, mean (SD), kg 53.6 (3.9) 52.7 (3.6) 53.3 (3.3)
Duration of anesthesia, 
mean (SD), min
168.5 (23.1) 165.0 (18.9) 169.1 (21.1)
ASA status,17 no. (%)
  I 43 (72) 42 (70) 46 (77)
  II 17 (28) 18 (30) 14 (23)
Thyroid status, no. (%)
  Euthyroid 54 (90) 55 (92) 54 (90)
  Treated euthyroid 6 (10) 5 (8) 6 (10)
Prior steroid use, no. 0 0 0
ASA = American Society of Anesthesiologists.
*No significant between-group differences were found.
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was no significant difference between any of the groups in the incidence of these AEs, 
which were all relatively mild (Table IV). 
DISCUSSION
In the present study, the treatment groups were similar in terms of patient demo-
graphic characteristics, surgical procedure, anesthetic administered, pain intensity, 
and postoperative analgesic use. In addition, patients with a history of motion sick-
ness, smoking, and previous postoperative emesis had been excluded from the study. 
Therefore, the difference in incidence of PONV between the groups might be attribut-
able to the variation in antiemetic drugs administered.
Fujii and Tanaka8,11 reported that 85% to 88% of patients undergoing thyroidec-
tomy were free of emesis with ramosetron 0.3-mg prophylaxis, which was comparable 
with the results of the present study. 
Table II.  Emetic episodes and analgesic requirements in Korean women who underwent 
thyroidectomy (N = 180).
Variable
Ramosetron 
0.3 mg 
(n = 60)
Dexamethasone 
8 mg 
(n = 60)
Ramosetron 
0.3 mg + 
Dexamethasone 
8 mg 
(n = 60)
P Overall 
(P1, P2)
Total PONV, no. 
(%) (95% CI)
8 (13)
(0.04–0.22)
      21 (35)
(0.23–0.47)
        6 (10)
(0.02–0.18)
0.002 
(0.03, 0.006)
Nausea, no. (%) 
(95% CI)
       5 (8)
(0.01–0.15)
12 (20)
(0.10–0.30)
        4 (7)
(0.01–0.13)
0.064
Vomiting, no. (%) 
(95% CI)
       3 (5)
(0.00–0.11)
        9 (15)
(0.06–0.24)
        2 (3)
(0.00–0.07)
0.066
Nausea severity, 
median 
(25th–75th 
percentiles)*
0 (0–0) 0 (0–4) 0 (0–0) 0.003 
(0.033, 0.009)
Rescue 
antiemetic drugs, 
no. (%) (95% CI)
       4 (7)
(0.01–0.13)
      16 (27)
(0.16–0.38)
        3 (5)
(0.00–0.11)
0.001
(0.018, 0.006)
Postoperative 
pain, median 
(25th–75th 
percentiles)†
4 (3–5) 4 (3–5) 5 (4–5) –
Postoperative 
ketorolac use, 
no. (%)
     27 (45)       26 (43) 29 (48) –
P1 = dexamethasone group versus ramosetron group; P2  = dexamethasone group versus dexamethasone + 
ramosetron group; PONV = postoperative nausea and vomiting.
*Scale: 0 = no nausea to 10 = nausea as bad as it could be. 
†Scale: 0 = no pain to 10 = the worst pain imaginable.
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Our findings indicated that the efficacy of the combination of ramosetron and 
dexamethasone was significantly better than that of dexamethasone alone. Contrary to 
our expectation, no significant difference was found between the effect of the combi-
nation and that of ramosetron alone, which was inconsistent with previous observa-
tions of other 5-HT3 antagonists.
14,19,20 These observations may have resulted from 
our using these drug combinations only in a selected population undergoing thyroid-
ectomy rather than other major surgeries or chemotherapy associated with high risks 
of emesis. Therefore, further studies are required to verify the efficacy of the combina-
tion of ramosetron and dexamethasone in other medical settings.
Dexamethasone has been used as an antiemetic in patients receiving highly emeto-
genic cancer chemotherapy21,22; it has been associated with significant reductions in 
the incidence of PONV.1,6,7,23,24 Meta-analysis of the results obtained in 5613 patients 
receiving moderately or highly emetogenic chemotherapy in 32 studies suggested 
that dexamethasone was significantly more effective than placebo or no treatment for 
complete protection against both acute (odds ratio [OR] = 2.22; 95% CI, 1.89–2.60) 
and delayed emesis (OR = 2.04; 95% CI, 1.63–2.56). The results were similar for 
complete protection against nausea.25 In the present study, we found that dexametha-
sone was significantly less effective in controlling PONV than ramosetron. Several 
studies have examined the effects of a single-dose application of dexamethasone before 
Table III.  Calculation of absolute risk reduction and number needed to treat (NNT) to 
prevent postoperative nausea and vomiting with the combination of dexa-
methasone and ramosetron.
Group NNT (95% CI)
Ramosetron 0.3 mg + dexamethasone 8 mg vs 4 (2.55 to 9.30) 
dexamethasone 8 mg 
Ramosetron 0.3 mg + dexamethasone 8 mg vs 30 (–12.29 to 6.75) 
ramosetron 0.3 mg 
Ramosetron 0.3 mg vs dexamethasone 8 mg 5 (2.74 to 14.61)
Table IV.  Incidence of adverse events (AEs) in Korean women who underwent thyroidec-
tomy (N = 180). Data are shown as number (%) (95% CI).
AE
Ramosetron 
0.3 mg 
(n = 60)
Dexamethasone 
8 mg 
(n = 60)
Ramosetron 0.3 mg + 
Dexamethasone 
8 mg (n = 60) P
Headache 12 (20)
(0.10–0.30)
         9 (15)
(0.06–0.24)
11 (18)
(0.08–0.28)
0.831
Dizziness 13 (22)
(0.12–0.32)
11 (18)
(0.08–0.28)
          9 (15)
(0.06–0.24)
0.677
Other AEs  
(eg, constipation, 
myalgia)
1 (2)
(0.00–0.06)
2 (3)
(0.00–0.07)
2 (3)
(0.00–0.07)
>0.99
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or after thyroidectomy on PONV.1,6,7,24 These studies indicated a reduced inci-
dence of PONV after thyroidectomy in the dexamethasone groups (20%–28%) 
compared with controls who received placebo (51%–76%). The incidence of 
PONV in dexamethasone groups in these studies was comparable to that in the 
present study.
This study had several limitations. The original design included a placebo control 
group, but the institutional review board at our center decided that this would not be 
ethical, as the patients studied were at high risk of developing PONV. In addition, a 
limited population was recruited according to exclusion criteria, and therefore the 
results may not be widely applicable to men or to patients undergoing other proce-
dures. Therefore, definitive conclusions regarding the effectiveness of the dexametha-
sone and ramosetron combination treatment relative to either agent alone cannot be 
reached. Other studies are required to address this issue.
The high cost of ramosetron may limit its widespread clinical application. Further 
studies are required to assess the cost savings or increased expenditure with the use of 
ramosetron in addition to antiemetic prophylaxis. Patients consider PONV to be one 
of the most undesirable postoperative symptoms, and it is one of the most common 
reasons for poor patient satisfaction rating in the postoperative period. Therefore, 
prophylactic antiemetic medication is highly recommended. In one study, patients 
associated a value with the avoidance of PONV and were willing to pay between US 
$56 and US $100 (2001) for a completely effective antiemetic.26 In our study, ramose-
tron appeared to be more effective than dexamethasone. Therefore, prophylactic use of 
ramosetron or another potent antiemetic should be considered when treating patients 
at high risk for PONV.
CONCLUSIONS
The combination of ramosetron and dexamethasone was more effective in reducing 
PONV than was dexamethasone monotherapy. However, the combination did not 
show additional benefits compared with ramosetron alone in preventing PONV after 
thyroidectomy in these Korean women.
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